The supply of a medicinal product without a marketing authorisation under national provisional permissions of use does not generally prevent an SPC.

The scope of protection of an SPC for a virus may be broader than the specific virus strain mentioned in the marketing authorization.

Today, the EFTA Court ruled on two important SPC issues

California’s Safer Consumer Products (SCP) regulations became effective October 1, 2013. These regulations apply to any “product or part of the product that is used, bought, or leased for use by a person for any purposes.” Given this ample language, the regulations have the potential to affect a wide range of industries and parties in